KRAS mutations were found in the plasma of 3/19 patients with high‐grade intraepithelial neoplasia (15.8%), 1/54 patients with adenomas (1.8%), and none of the patients with hyperplasia 14. Here, KRAS is linked to intraepithelial neoplasia.